Loading…
Loading…
Rated 2 (not 1) on the disclosed BRL 300 million (~USD 51.7 million) subsidy pool — the same order of magnitude as the parallel BRL 300 million FINEP "Rodada 2" calls for defense and agro-industrial chains (also severity 2) filed the same day. This is an open, multi-company, multi-project call rather than a single recipient, which keeps it at the low end of the severity-2 band.
FINEP runs "Mais Inovação Brasil" as a standing series of sector-specific subsidy rounds funded through the FNDCT (Fundo Nacional de Desenvolvimento Científico e Tecnológico) under MCTI (Ministério da Ciência, Tecnologia e Inovação), aligned with the Nova Indústria Brasil reindustrialization policy. This call targets companies developing technologically risky, innovative products or processes for the Complexo Econômico-Industrial da Saúde (health economic-industrial complex), with a stated aim of developing products and processes strategic to Brazil's public health system (SUS). Funding is non-repayable economic subsidy (subvenção econômica); Scientific, Technological and Innovation Institutions (ICTs) may participate as partners. The call is open nationwide, with a minimum regional reserve of BRL 90 million for projects executed in the North, Northeast or Center-West.
same day, 2026-02-06 (see also the BRL 300 million defense- industrial-base grant, the BRL 300 million agro-industrial chains grant, the BRL 500 million energy-transition round, and the BRL 215.2 million mineral-transformation grant) — cumulative FNDCT exposure across simultaneous calls is larger than any single round suggests.
reinforcing Brazil's push to reduce import dependence on active pharmaceutical ingredients and health-sector chemical inputs.
disbursements and beneficiary companies will only become visible well after this filing; no company_refs yet exist.
round, and in what amounts, once the window closes or the budget is exhausted.
Northeast/Center-West) materially shifts the geographic distribution of Brazil's pharmaceutical R&D capacity.